Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)
The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
Objective This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in adults with type 1 diabetes. Research design and methods The primary end point was change from baseline in HbA 1c after 26 weeks. After an 8-week run-in, subjects were randomized (1:1:1) to double-blind mealtime faster aspart ( n = 381), IAsp ( n = 380), or open-label postmeal faster aspart ( n = 382)-each with insulin detemir. Results HbA 1c was reduced in both treatment groups, and noninferiority to IAsp was confirmed for both mealtime and postmeal faster aspart (estimated treatment difference [ETD] faster aspart-IAsp, mealtime, -0.15% [95% CI -0.23; -0.07], and postmeal, 0.04% [-0.04; 0.12]); mealtime faster aspart statistically significantly reduced HbA 1c versus IAsp ( P = 0.0003). Postprandial plasma glucose (PPG) increments were statistically significantly lower with mealtime faster aspart at 1 h (ETD -1.18 mmol/L [95% CI -1.65; -0.71], -21.21 mg/dL [-29.65; -12.77]; P P = 0.0375) after the meal test; superiority to IAsp for the 2-h PPG increment was confirmed. The overall rate of severe or blood glucose-confirmed (plasma glucose Conclusions Faster aspart effectively improved HbA 1c , and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp. Subjects randomized to postmeal faster aspart for all meals maintained HbA 1c noninferior to that o…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are limited data comparing the latest basal insulin analogs degludec and glargine U300.1147,1148”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1148]
In the citing paper
“Results from comparative effectiveness meta-analyses suggest that each new class of oral noninsulin agents when added to metformin generally lowers A1C by approximately 0.7-1.0%(8-11 mmol/mol).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [11]
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Andrea, D., Kakuk, P., & Judit, S. (2014) · University of Debrecen Electronic Archive (University of Debrecen) · Cited by 1,954
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Long-Term Complications of Diabetes Mellitus
Nathan, D. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306103282306 · Cited by 1,495
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia was defined according to the American Diabetes Association classification (26) and BG-confirmed hypoglycemia by a PG value ,3.”
MethodSelf-citationPeyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“4%) of people with diabetes would like their insulin regimen to fit with their daily life changes (23), and the option to take their insulin dose after a meal when necessary may address this need.”
BackgroundFrost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323
Home, P. D., Lindholm, A., Riis, A., & for the European Insulin Aspart Study Group (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00380.x · Cited by 232
Raskin, P., Guthrie, R. A., Leiter, L., Riis, A., & Jovanovic, L. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.583 · Cited by 230
Research works printed but not linked: 5
- Andersen, 2015, Ultra-rapid BioChaperone insulin Lispro (BC-LIS): linear dose-response and faster absorption than insulin Lispro (LIS), Diabetologia, 58, S449
- Hirsch, 2014, Recombinant human hyaluronidase pretreatment of CSII cannula sites provides comparable glycemic control with reduced hypoglycemia in T1DM compared to usual CSII, Diabetes, 63, 85-LB
- Høiberg-Nielsen, 2016, Mechanistic analysis into the mode of action of niacinamide in faster-acting insulin aspart, Diabetes Technol Ther, 18, A291
- Rodbard, 2016, Adding faster-acting insulin aspart to basal insulin significantly improved glycemic control: the onset 3 trial, Diabetes, 65, A64
- 2016, Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes, Endocr Rev, 37, FRI697
Cited by
Items 101–177 of 177
Faster and faster: meeting the challenges of delayed insulin action during pregnancy
Feig, D. S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00259-0 · Cited by 4
Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée
Monnier, L., Colette, C., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00178-4 · Cited by 5
Glycemic control after switching to faster aspart in adults with type 1 diabetes
Fadini, G. P., Boscari, F., Falaguasta, D., Ferretto, S., Maran, A., Avogaro, A., & Bruttomesso, D. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01745-2 · Cited by 4
Ranjan, A. G., Schmidt, S., & Nørgaard, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16326 · Cited by 3
Aleppo, G., Bode, B. W., & Carlson, A. L. (2022) · Clinical Diabetes · doi:10.2337/cd21-0056 · Cited by 3
Self-citationVillar‐Taibo, R., Sanz-Pastor, A. G., Fernández-Rubio, E., Galindo, D. E. B., Simó-Servat, A., & Ampudia‐Blasco, F. J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0524 · Cited by 4
“22,24 However, the rate and incidence of severe or documented hypoglycemia were similar between URAI and RAI in those trials, and there is even some evidence in favor of URAI in terms of reducing nocturnal hypoglycemia.”
InfluentialHeald, A. H., Stedman, M., Warner-Levy, J. J., Belston, L., Paisley, A. N., Jotić, A., Lalic, N. M., Gibson, M., Habte‐Asres, H. H., Whyte, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01647-x · Cited by 3
Cutruzzolà, A., Parise, M., Fiorentino, R., Romano, A., Molinaro, V., Gnasso, A., Molfetta, S. D., & Irace, C. (2022) · Nutrients · doi:10.3390/nu14163316 · Cited by 4
Lind, M., Catrina, S., Ekberg, N. R., Gerward, S., Halasa, T., Hellman, J., Hess, D., Löndahl, M., Qvist, V., & Bolinder, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01444-y · Cited by 5
Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?
Muchmore, D. B. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817750166 · Cited by 3
Glucocorticoid chronotherapy: a mini-review
Naafs, M. A. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00164 · Cited by 3
Type 1 Diabetes in Children and Adolescents
Hu, P., Name, M. A. V., Stephenson, K., Sikes, K. A., & Tamborlane, W. V. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_30 · Cited by 3
Treatment of cystic fibrosis-related diabetes
Kessler, L. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30042-1 · Cited by 3
Júnior, W. S. D. S., Gabbay, M. A. L., Lamounier, R. N., Calliari, L. E., & Bertoluci, M. C. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00949-z · Cited by 4
Haahr, H. L., & Heise, T. (2020) · Diabetes Mellitus · doi:10.14341/dm12357 · Cited by 2
Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2023)
Lechleitner, M., Kaser, S., Hoppichler, F., Roden, M., Weitgasser, R., Ludvik, B. H., Fasching, P., Winhofer, Y., Kautzky‐Willer, A., Schernthaner, G., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02182-8 · Cited by 2
Treatment Approaches and Challenges
Malboosbaf, R., & Hatami, N. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010005 · Cited by 2
Ultrafast-acting insulin: pharmacological properties and their impact on clinical aspects
Суплотова, Л. А., & Tilkiyan, A. S. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-262 · Cited by 2
Are newer insulins always the better option?
Malkani, S. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000469 · Cited by 2
Treatment of type 1 diabetes complicated by problematic hypoglycemia
Jacob, P., CHANDRAN, S. R., & Choudhary, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00032-0 · Cited by 3
Amigo, J. G. D. B., García, A. G., Fernández, P. D., Llamas, M. F., Bravo, M. L. T., Jiménez, J. M., & Lozano, M. F. (2020) · Anales de Pediatría · doi:10.1016/j.anpedi.2020.11.002 · Cited by 2
Fast-acting insulin aspart - from insulin portraits to patient portraits
Demidova, T. Y., & Izmaylova, M. Y. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-8-16 · Cited by 2
Insulin Pumps and Artificial Pancreas
Taleb, N., Gingras, V., & RABASA-LHORET, R. P. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65407-7 · Cited by 3
Komatsu, M., Ekelund, M., Horio, H., & Kadowaki, T. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0606 · Cited by 2
Girsh, Y. V., Kiyaev, A. V., Slovak, M. A., Korneva, I. V., Промин, И. А., Yusupova, N. A., & Savelyev, L. I. (2022) · Diabetes Mellitus · doi:10.14341/dm12838 · Cited by 2
Liu, H., Xiong, Y., Chen, X., Yu, H., Lan, L., He, W., Wang, W., Zhuang, Y., Deng, L., Huang, K., et al. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2463085 · Cited by 1
Heise, T., Hövelmann, U., Nosek, L., Sassenfeld, B., Thomsen, K. M. D., & Haahr, H. L. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0539-7 · Cited by 1
Paediatric type 1 diabetes 2018: Clinical and research insights
Zborovski, S., & Mahmud, F. H. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxx214 · Cited by 2
Developments in the Management of Type 1 and Type 2 Diabetes
Mathieu, C. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.13 · Cited by 2
Self-citationA Reproducibility Rule for Choosing the Number of Imputations When Reporting Clinical Trials
Gorst‐Rasmussen, A. (2020) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2020.1784781 · Cited by 1
Contrôle de la glycémie post-prandiale : apport des nouvelles formulations d’insuline ultra-rapides
Reznik, Y., & Jubin, L. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.09.004 · Cited by 1
Au-delà des insulines actuelles : des réalisations prometteuses et quelques désillusions
Monnier, L., Colette, C., Azrak, A. E., Essekat, N., & Rochd, D. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.12.002 · Cited by 2
Weiss, L. M., Reix, P., Mosnier-Pudar, H., Ronsin, O., Beltrand, J., Reynaud, Q., Mély, L., Burgel, P., Stremler, N., Rakotoarisoa, L., et al. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.01.001 · Cited by 4
Significant publications in diabetes pharmacotherapy and technology in 2020
Clements, J. N., Franks, R. B., Isaacs, D. M., Malloy, K., Meade, L. T., Reece, S. W., Reid, D. J., & Ward, E. D. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2187779 · Cited by 1
RetractedZelinska, N. (2020) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2020-4-39 · Cited by 1
Bode, B. W., Bowering, K., & Russell-Jones, D. L. (2018) · Diabetes Care · doi:10.2337/dci17-0051 · Cited by 1
Self-citationHeise, T., & Biester, T. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-116018
Real-World Challenges of Controller Adaptation with the Artificial Pancreas
Bally, L., & Thabit, H. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0310
Möglichkeiten und Grenzen der aktuellen Insulintherapie
Forst, T. M. (2017) · Info Diabetologie · doi:10.1007/s15034-017-0976-7
Möglichkeiten und Grenzen der aktuellen Insulintherapie: Diabetes mellitus
Forst, T. M. (2018) · CME · doi:10.1007/s11298-018-6417-7
Wu, T., Marathe, C. S., Horowitz, M., Jones, K. L., & Rayner, C. K. (2018) · Diabetes Care · doi:10.2337/dc17-1916
Analysis of “Laboratory and Benchtop Performance of a Mealtime Insulin Delivery System”
Zijlstra, E. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818767940
Postprandiale Hyperglykämie ist gefährlich
Stiefelhagen, P. (2018) · Info Diabetologie · doi:10.1007/s15034-018-1326-0
Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus
Sabet, S., Condren, M. E., Boston, A., Doak, L. C., & Chalmers, L. J. (2018) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-23.5.351 · Cited by 1
Peptide Drug Design for Diabetes and Related Metabolic Diseases
Kaarsholm, N. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_13
Aktuelle Therapien und Technologien in der Kinderdiabetologie
Bartelt, H., Klamt, S., Thiele, A. G., Sergeyev, E., Kieß, W., & Kapellen, T. M. (2020) · Kinder- und Jugendmedizin · doi:10.1055/a-1065-7281
A prandialis glükózkontroll elérése gyors aszpart inzulinnal
Kis, J. T. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.8 · Cited by 1
Rasante Weiterentwicklung der Therapiemöglichkeiten
Kapellen, T. M. (2020) · Pädiatrie · doi:10.1007/s15014-020-2342-9
Faster Insulin Aspart - a new prandial insulin analogue
Flekač, M. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.138
Faster Aspart: a fast-acting insulin analog for an optimal glycemic control
Irace, C. (2021) · The Journal of AMD · doi:10.36171/jamd21.24.3.5
Aproximación florística al barranco de la Tosquilla de la Iglesuela del Cid (Teruel)
García, R. P. I. (1992) · Teruel: Revista del Instituto de Estudios Turolenses · Cited by 2
Insulins and Insulin Delivery Devices
Choudhary, P., & Jacob, P. (2022) · doi:10.1093/med/9780198870197.003.0252 · Cited by 1
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Hamarneh, Y. N. A., Siemens, R. L., Townsend, K. J., & Tsuyuki, R. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-11775-7_12
Short‐acting Insulin Analogues
and, K. H., & McKay, G. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch8
Girsh, Y. V., & Алимхановна, Ю. Н. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-2-21-26
Insulin: 100 years but not over the hill! A treatment with potential for renewal
Valenzano, M. (2022) · The Journal of AMD · doi:10.36171/jamd22.25.2
de Medeiros, M. S., Gallani, J. D. A., & Swiech, J. N. D. (2022) · Research Society and Development · doi:10.33448/rsd-v11i15.36858
100 años de la comercialización de la insulina. Una carrera aún por terminar
Martínez, E. A., Miravet-Jiménez, S., & Simarro, F. L. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.11.005
Davidson, M. B. (2023) · Clinical Diabetes · doi:10.2337/cd22-0106
Significant publications in diabetes pharmacotherapy and technology in 2020
Clements, J. N., Franks, R. B., Isaacs, D. M., Malloy, K., Meade, L. T., Reece, S. W., Reid, D. J., & Ward, E. D. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2187618
100 years of the commercialization of insulin: A race yet to end
Martínez, E. A., Miravet-Jiménez, S., & Simarro, F. L. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.11.006
Meyer, L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.04.007
Multicomponent Insulin Regimens
Steenkamp, D. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407694.ch06
Objetivos del tratamiento de la diabetes mellitus tipo 1
Cebada, A. B., da Silva, J. K. H., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.002 · Cited by 2
Insulinothérapie fonctionnelle
Zimmermann, C., Collette, A., & Borot, S. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)43373-8
Demidova, T. Y., & Titova, V. V. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.10.203482 · Cited by 1
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Neumiller, J. J., & McKeirnan, K. C. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch03
Management of Hyperglycemia in Type 1 Diabetes Mellitus
Neumiller, J. J. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch02
Hamarneh, Y. N. A., Liu, S., Siemens, R. L., Townsend, K. J., & Tsuyuki, R. T. (2025) · Springer eBooks · doi:10.1007/978-3-032-10050-4_14
Effectiveness of Using Patient-Defined Meal Sizes to Determine Bolus Doses of Insulin
Davidson, M. B., Scarlett, L., Duran, P. A., JENNE, K. W., Shinn, P., & Woodcock, E. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0018
Makeeva, T. I., Koltakova, M. P., Федоринин, А. А., Bezlepkina, O. B., & Лаптев, Д. Н. (2026) · Diabetes Mellitus · doi:10.14341/dm13395
Glycemic management in adults with type 1 diabetes
Koliaki, C. C., & Liatis, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00317-4
Guo, Y., Mei, Y., Bongaerts, B. W. C., Metzendorf, M., Fullerton, B., Siebenhofer, A., Jeitler, K., Horvath, K., Semlitsch, T., Berghold, A., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012161.pub2
Rakotoarisoa, L., Mulette, P., Chiron, R., Ramel, S., Ronsin, O., Weiss, L., Stremler, N., Gabsi, A., Mély, L., Silva, I. D., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113544
Metadata
- Authors
- Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., Graungaard, T., & Bergenstal, R. M.
- Affiliations
- Royal Surrey County Hospital (GB)
- Atlanta Diabetes Associates (US)
- Department of Endocrinology, Diabetology, and Metabolism, Antwerp University Hospital, Antwerp, Belgium
- Mossakowski Medical Research Institute, Polish Academy of Sciences (PL)
- University of Sheffield (GB)
- Universitair Ziekenhuis Leuven (BE)
- Scripps Whittier Diabetes Institute, Scripps Health, San Diego, CA
- Institute of Diabetes Research, Münster, Germany
- University of Manitoba (CA)
- Novo Nordisk (Denmark) (DK)
- Park Nicollet Health Services (US)
- Corresponding author
- Russell-Jones, David
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-03-29
- Volume
- 40
- Issue
- 7
- Pages
- 943-950
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2598553007
- Cited by
- 177
- References
- 23
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 21 · 2021: 22 · 2020: 23 · 2019: 22 · 2018: 35 · 2017: 14
- FWCI
- 20.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- fast-acting insulin aspart, insulin aspart, type 1 diabetes, multiple daily insulin injections, insulin detemir, glycemic control, HbA1c, postprandial blood glucose, hypoglycemia, non-inferiority, mealtime insulin, insulin analogues, treat-to-target, adults with type 1 diabetes
- MeSH terms
- Insulin Detemir, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Male, Middle Aged, Body Mass Index, Postprandial Period, Endpoint Determination, Insulin Aspart, Meals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.